Latest news with #SIL204
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics announces preclinical results on SIL204
Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung, NSCLC, cancer cell lines. These results significantly expand SIL204's therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs. Following the Company's recent announcement of completion of preclinical studies, a comprehensive analysis of the data has revealed that SIL204 effectively inhibited the proliferation and metabolic activity of human cancer cell lines harboring KRAS G12D mutations across multiple cancer types, resulting in the following obvervations: The data reveals SIL204 successfully inhibited the proliferation and metabolic activity of human cancer cell lines harboring a specific KRAS mutation: GP2D, A427 and Panc-1, in a statistically significant manner. The significant inhibition was observed in a dose-dependent manner down to nanomolar concentrations. As observed in the left hand graph below, a dose-dependent reduction in cell viability was noted in GP2D colorectal cancer cells, even in the absence of external additives, due to the lipid end of SIL204. Notably, as can be seen in the right hand graph below, the Company observed an inhibition rate of approximately 90% in the presence of SIL204 in GP2D colorectal cancer cells. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SLXN: Disclaimer & DisclosureReport an Issue Silexion Therapeutics Receives Nasdaq Delisting Notice Silexion Completes Key Preclinical Studies for SIL204 Silexion Therapeutics completes preclinical studies on SIL204 Silexion Therapeutics' Promising Future: Buy Rating Backed by Expanding Market Potential and Strong Financial Position Silexion Therapeutics Partners with Catalent for SIL204 Development
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer
Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) ('Silexion' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of a comprehensive preclinical study assessing SIL204's therapeutic potential across multiple cancer types beyond pancreatic cancer. The Company is currently finalizing its analysis of the data and expects to announce comprehensive results within the next few days. The now-completed studies evaluated SIL204, the Company's next-generation RNAi therapeutic candidate, in multiple cancer cell lines harboring KRAS mutations: GP2D (colorectal cancer), A427 (lung cancer), and Panc-1 (pancreatic cancer). These cancer types were strategically selected based on their high prevalence of KRAS mutations and significant unmet medical needs. "Completing this expanded preclinical evaluation represents an important milestone in our SIL204 development program," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "While our initial focus has been on pancreatic cancer, we recognized the potential of our RNAi approach to address other KRAS-driven malignancies. We look forward to sharing the detailed results from these studies in the coming days after completing the final analysis of the studies data. If positive, we believe these results have the potential to significantly expand our development strategy going forward." KRAS mutations are among the most common oncogenic drivers in human cancers, occurring in roughly 90% of pancreatic cancers, about 45% of colorectal cancers, and around 35% of non-squamous non-small-cell lung cancers. Together, these three indications underpin global treatment markets already worth well over US $30 billion a year1, yet most KRAS variants remain difficult to drug with small-molecule or antibody approaches—underscoring the potential significance of Silexion's RNAi-based strategy. About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, ongoing preclinical studies evaluating SIL204 in colorectal and lung cancer applications, potential expansion of development strategy, plans to announce comprehensive results in the coming days, and the therapeutic potential of SIL204 across multiple cancer types, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them, or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied by those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@ Markets & IR ContactArx Capital MarketsNorth American Equities Desksilexion@ 1 (i) Pancratic Cancer Treatment Mark; (ii) Colorectal Cancer Therapeutics Market; (iii) NSCLC Lunc Cancer Therapeutics MarketError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-03-2025
- Business
- Yahoo
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion's new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company shares its strategic roadmap for SIL204's clinical development including plans to initiate human trials in H1 2026 Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion' or the 'Company'), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic progression with intratumoral administration to focus on primary tumors, offering a comprehensive approach to treating KRAS-driven pancreatic cancer. The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that systemic administration of SIL204 significantly inhibits tumor growth in clinically relevant orthotopic models of pancreatic cancer. This dual-route approach is designed to address the aggressive nature of KRAS-driven cancers, which are characterized by high mortality and limited treatment options. 'Our expanded development plan reflects the strength of recent preclinical data and our commitment to addressing the complexities of KRAS-driven cancers,' said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. 'By combining localized and systemic delivery strategies, we aim to offer a more comprehensive solution to one of the most challenging cancers to treat. With our goal of initiating human trials in the H1 2026, we look forward to advancing this approach into clinical trials and delivering meaningful progress for patients in need.' Based on the promising clinical and preclinical data and as part of the expanded development plan, Silexion has established a clear development pathway for SIL204. Building on the Phase 2 clinical results from its first-generation product (siG12DLoder) and the recent orthotopic model studies showing SIL204's ability to reduce metastases, the Company plans to conduct additional toxicology and pharmacodynamic studies throughout the remainder of 2025, followed by potential regulatory submissions to the Israel Ministry of Health in H2 2025 and to the European Union in H1 2026. These submissions would initiate the next stage of clinical development for SIL204 in patients with advanced localized KRAS-driven pancreatic expanded development plan is supported by compelling data from both Silexion's clinical and preclinical programs. The Company's first-generation product, siG12DLoder, demonstrated an overall survival benefit in Phase 2 clinical trials. Building on this foundation, recent preclinical studies with SIL204 showed that subcutaneous administration significantly reduces metastases to secondary organs in orthotopic models, where human pancreatic tumor cells are placed in their natural environment (the pancreas). Pharmacokinetic data in rats further validates this approach, showing sustained SIL204 levels in orthotopic models of pancreatic secondary tumors, for approximately two months following a single subcutaneous administration. The Company will be presenting this expanded development plan alongside recently reported preclinical developments at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference taking place today (March 28th, 2025), providing industry experts and stakeholders with an in-depth look at Silexion's innovative approach to KRAS-driven cancer therapies. About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, ongoing studies and plans to initiate further studies and make regulatory submissions are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the company, including the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@ Markets & IR ContactArx | Capital Markets AdvisorsNorth American Equities Desksilexion@ in to access your portfolio
